Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

161.35
+2.611.64%
Post-market: 161.350.00000.00%18:06 EST
Volume:1.10M
Turnover:177.66M
Market Cap:7.94B
PE:-105.46
High:163.33
Open:160.44
Low:156.58
Close:158.74
52wk High:228.88
52wk Low:91.86
Shares:49.22M
Float Shares:48.62M
Volume Ratio:0.72
T/O Rate:2.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5300
EPS(LYR):0.2004
ROE:-2.19%
ROA:4.33%
PB:2.33
PE(LYR):805.11

Loading ...

Earning Preview: Charles River Laboratories this quarter’s revenue is expected to increase by 0.34%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 11

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

GlobeNewswire
·
Feb 14

Charles River Laboratories International Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Feb 13

Charles River Laboratories International Inc. Stock Slides 8.4%, Underperforms Peers

Dow Jones
·
Feb 12

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EST

Reuters
·
Feb 12

Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Feb 10

Regenxbio falls 21% to $8.10 after FDA issues CRL for BLA for RGX-121

TIPRANKS
·
Feb 10

Regenxbio says FDA issues CRL regarding BLA for RGX-121

TIPRANKS
·
Feb 10

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 07

Charles River Laboratories International Inc. Stock Slides 8.9%, Underperforms Peers

Dow Jones
·
Feb 06

AstraZeneca reports FDA issued CRL for BLA for subcutaneous Saphnelo

TIPRANKS
·
Feb 03

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 03

What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?

Benzinga_recent_news
·
Feb 03

Buy Rating Maintained on Aquestive Therapeutics as FDA CRL Seen as Operational Setback with Manageable Risk and Attractive Long‑Term Risk‑Reward

TIPRANKS
·
Feb 03

Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

TIPRANKS
·
Feb 02

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

GlobeNewswire
·
Feb 02

Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS

GlobeNewswire
·
Feb 02

Corcept falls as FDA reveals it warned of CRL rejection for relacorilant

TIPRANKS
·
Jan 31

Charles River Laboratories International Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Jan 29

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jan 27